|
CLK4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.35269999979037E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62599999999902E-05 |
| Normal-vs-Stage2 |
1.52450000001636E-06 |
| Normal-vs-Stage3 |
5.67180002963852E-09 |
| Normal-vs-Stage4 |
1.176610E-03 |
| Stage1-vs-Stage2 |
6.383600E-02 |
| Stage1-vs-Stage3 |
1.648480E-02 |
| Stage1-vs-Stage4 |
6.532400E-01 |
| Stage2-vs-Stage3 |
9.065600E-01 |
| Stage2-vs-Stage4 |
3.763400E-01 |
| Stage3-vs-Stage4 |
3.571800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.1887999995519E-07 |
| Normal-vs-AfricanAmerican |
5.516000E-03 |
| Normal-vs-Asian |
4.945700E-02 |
| Caucasian-vs-AfricanAmerican |
5.633000E-01 |
| Caucasian-vs-Asian |
2.627800E-02 |
| AfricanAmerican-vs-Asian |
3.765600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.62650000000398E-05 |
| Normal-vs-Female |
4.2478999984219E-08 |
| Male-vs-Female |
5.002800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.592300E-04 |
| Normal-vs-Age(41-60Yrs) |
2.47560000277147E-08 |
| Normal-vs-Age(61-80Yrs) |
2.64750000000813E-06 |
| Normal-vs-Age(81-100Yrs) |
1.53091999999244E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.612100E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.938000E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.663400E-03 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.260400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.033000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.599450E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.09949999952342E-07 |
| Classical-VS-Follicular |
1.085170E-01 |
| Classical-VS-Other |
1.537160E-01 |
| Classical-VS-Normal |
2.16529999998993E-05 |
| Tall-VS-Follicular |
3.738000E-03 |
| Tall-VS-Other |
3.996400E-02 |
| Tall-VS-Normal |
3.495703726486E-11 |
| Follicular-VS-Other |
6.482300E-02 |
| Follicular-VS-Normal |
2.10020000002142E-06 |
| Other-VS-Normal |
7.572200E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.17439999947067E-08 |
| Normal-vs-N1 |
1.540160E-01 |
| N0-vs-N1 |
4.192200E-02 |
|
|
